Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Rigel Pharmaceuticals Stock Quote

Rigel Pharmaceuticals (NASDAQ: RIGL)

Price as of June 12, 2024, 11:55 a.m. ET

Rigel Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
RIGL -38.18% -51.89% -13.61% -98%
S&P +23.89% +85.89% +13.20% +301%

Rigel Pharmaceuticals Company Info

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

News & Analysis

The Fool has written over 100 articles on Rigel Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.